Abstract
Purpose of review
We review the prevention and treatment of postoperative endophthalmitis.
Recent findings
Postoperative endophthalmitis is rare but has potentially blinding consequences. There is no consensus on prevention, but there are a few controlled studies with methods of decreasing the infection rate, such as use of povidone iodine and intracameral antibiotics. There remains only one randomized controlled study (Endophthalmitis Vitrectomy Study or EVS) on the treatment of postoperative endophthalmitis, but there are retrospective studies which examine the timing and various methods of vitrectomy and intravitreal antibiotics.
Summary
The application of povidone iodine remains a proven method of preventing endophthalmitis, but evidence suggests that intracameral antibiotics further minimize this risk. Further research is needed to define the efficacy of intravitreal antibiotics at the time of cataract surgery. There are many questions regarding treatment, including performance of vitrectomy for eyes with visual acuities better than light perception, smaller vitrectomy port sizes, and intravitreal antibiotics and/or oral steroids.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Friling E, Lundström M, Stenevi U, Montan P. Six-year incidence of endophthalmitis after cataract surgery: Swedish national study. J Cataract Refract Surg. 2013;39(1):15–21.
Keay L, Gower EW, Cassard SD, Tielsch JM, Schein OD. Postcataract surgery endophthalmitis in the United States: analysis of the complete 2003 to 2004 Medicare database of cataract surgeries. Ophthalmology. 2012;119(5):914–22.
Schmier JK, et al. An updated estimate of costs of endophthalmitis following cataract surgery among Medicare patients: 2010-2014. Clin Ophthalmol. 2016;10:2121–7.
Cullen KA, Hall MJ, Golosinskiy A. Ambulatory surgery in the United States. Natl Health Stat Rep. 2006;2009(11):1–25.
Behndig A, Cochener B, Güell JL, Kodjikian L, Mencucci R, Nuijts RMMA, et al. Endophthalmitis prophylaxis in cataract surgery: overview of current practice patterns in 9 European countries. J Cataract Refract Surg. 2013;39(9):1421–31.
Olson RJ, Braga-Mele R, Chen SH, Miller KM, Pineda R 2nd, Tweeten JP, et al. Cataract in the adult eye preferred practice pattern(R). Ophthalmology. 2017;124(2):P1–p119.
Chang DF, et al. Antibiotic prophylaxis of postoperative endophthalmitis after cataract surgery: results of the 2014 ASCRS member survey. J Cataract Refract Surg. 2015;41(6):1300–5.
Kelkar AS, Chang DF, Kelkar JA, Mehta HM, Lahane T, Parekh R. Antibiotic prophylaxis practice patterns for cataract surgery in India—results from an online survey. Indian J Ophthalmol. 2017;65(12):1470–4.
Grzybowski A, Schwartz SG, Matsuura K, Ong Tone S, Arshinoff S, Ng JQ, et al. Endophthalmitis prophylaxis in cataract surgery: overview of current practice patterns around the world. Curr Pharm Des. 2017;23(4):565–73.
Meyer JJ, Polkinghorne PJ, McGhee CN. Cataract surgery practices and endophthalmitis prophylaxis by New Zealand ophthalmologists. Clin Exp Ophthalmol. 2016;44(7):643–5.
Katibeh M, Ziaei H, Mirzaei M, Eskandari A, Moein H, Kalantarion M, et al. Perioperative prophylaxis for endophthalmitis after cataract surgery in Iran. J Ophthalmic Vis Res. 2015;10(1):33–6.
Haripriya A, Baam ZR, Chang DF. Endophthalmitis prophylaxis for cataract surgery. Asia Pac J Ophthalmol (Phila). 2017;6(4):324–9.
Ciulla TA, Starr MB, Masket S. Bacterial endophthalmitis prophylaxis for cataract surgery: an evidence-based update. Ophthalmology. 2002;109(1):13–24.
Nentwich MM, Ta CN, Kreutzer TC, Li B, Schwarzbach F, Yactayo-Miranda YM, et al. Incidence of postoperative endophthalmitis from 1990 to 2009 using povidone-iodine but no intracameral antibiotics at a single academic institution. J Cataract Refract Surg. 2015;41(1):58–66.
Speaker MG, Menikoff JA. Prophylaxis of endophthalmitis with topical povidone-iodine. Ophthalmology. 1991;98(12):1769–75.
Ophthalmologists, T.R.C.O. Cataract surgery guidelines. 2010.
Nguyen CL, Oh LJ, Wong E, Francis IC. Povidone-iodine 3-minute exposure time is viable in preparation for cataract surgery. Eur J Ophthalmol. 2017;27(5):573–6.
Shimada H, et al. Reduced anterior chamber contamination by frequent surface irrigation with diluted iodine solutions during cataract surgery. Acta Ophthalmol. 2017;95(5):e373–8.
Ta CN, Singh K, Egbert PR, de Kaspar HM. Prospective comparative evaluation of povidone-iodine (10% for 5 minutes versus 5% for 1 minute) as prophylaxis for ophthalmic surgery. J Cataract Refract Surg. 2008;34(1):171–2.
Mino de Kaspar H, et al. Prospective randomized comparison of 2 different methods of 5% povidone-iodine applications for anterior segment intraocular surgery. Arch Ophthalmol. 2005;123(2):161–5.
Li B, Nentwich MM, Hoffmann LE, Haritoglou C, Kook D, Kampik A, et al. Comparison of the efficacy of povidone-iodine 1.0%, 5.0%, and 10.0% irrigation combined with topical levofloxacin 0.3% as preoperative prophylaxis in cataract surgery. J Cataract Refract Surg. 2013;39(7):994–1001.
Wu PC, Li M, Chang SJ, Teng MC, Yow SG, Shin SJ, et al. Risk of endophthalmitis after cataract surgery using different protocols for povidone-iodine preoperative disinfection. J Ocul Pharmacol Ther. 2006;22(1):54–61.
Hosseini H, Ashraf MJ, Saleh M, Nowroozzadeh MH, Nowroozizadeh B, Abtahi MB, et al. Effect of povidone-iodine concentration and exposure time on bacteria isolated from endophthalmitis cases. J Cataract Refract Surg. 2012;38(1):92–6.
Nentwich MM, Rajab M, Ta CN, He L, Grueterich M, Haritoglou C, et al. Application of 10% povidone iodine reduces conjunctival bacterial contamination rate in patients undergoing cataract surgery. Eur J Ophthalmol. 2012;22(4):541–6.
Vasavada AR, Gajjar D, Raj SM, Vasavada V, Vasavada V. Comparison of 2 moxifloxacin regimens for preoperative prophylaxis: prospective randomized triple-masked trial. Part 1: aqueous concentration of moxifloxacin. J Cataract Refract Surg. 2008;34(8):1379–82.
Li B, Miño de Kaspar H, Haritoglou C, Kook D, Kampik A, Sheng M, et al. Comparison of 1-day versus 1-hour application of topical neomycin/polymyxin-B before cataract surgery. J Cataract Refract Surg. 2015;41(4):724–31.
Ta CN, Sinnar S, He L, Myung D, de Kaspar HM. Prospective randomized comparison of 1-day versus 3-day application of topical levofloxacin in eliminating conjunctival flora. Eur J Ophthalmol. 2007;17(5):689–95.
Holland EJ, et al. Antibiotic resistance in acute postoperative endophthalmitis. Ophthalmology. 2014;121(11 Suppl):S1–9. quiz S10–2
Kim SJ, Toma HS. Ophthalmic antibiotics and antimicrobial resistance a randomized, controlled study of patients undergoing intravitreal injections. Ophthalmology. 2011;118(7):1358–63.
Kim SJ, Toma HS. Antimicrobial resistance and ophthalmic antibiotics: 1-year results of a longitudinal controlled study of patients undergoing intravitreal injections. Arch Ophthalmol. 2011;129(9):1180–8.
Dave SB, Toma HS, Kim SJ. Ophthalmic antibiotic use and multidrug-resistant Staphylococcus epidermidis: a controlled, longitudinal study. Ophthalmology. 2011;118(10):2035–40.
Miyanaga M, Nejima R, Miyai T, Miyata K, Ohashi Y, Inoue Y, et al. Changes in drug susceptibility and the quinolone-resistance determining region of Staphylococcus epidermidis after administration of fluoroquinolones. J Cataract Refract Surg. 2009;35(11):1970–8.
Milder E, Vander J, Shah C, Garg S. Changes in antibiotic resistance patterns of conjunctival flora due to repeated use of topical antibiotics after intravitreal injection. Ophthalmology. 2012;119(7):1420–4.
Stringham JD, Relhan N, Miller D, Flynn HW Jr. Trends in fluoroquinolone nonsusceptibility among coagulase-negative Staphylococcus isolates causing Endophthalmitis, 1995-2016. JAMA Ophthalmol. 2017;135(7):814–5.
Hsu HY, Lind JT, Tseng L, Miller D. Ocular flora and their antibiotic resistance patterns in the midwest: a prospective study of patients undergoing cataract surgery. Am J Ophthalmol. 2013;155(1):36–44.e2.
Dave SB, Toma HS, Kim SJ. Changes in ocular flora in eyes exposed to ophthalmic antibiotics. Ophthalmology. 2013;120(5):937–41.
Nejima R, Shimizu K, Ono T, Noguchi Y, Yagi A, Iwasaki T, et al. Effect of the administration period of perioperative topical levofloxacin on normal conjunctival bacterial flora. J Cataract Refract Surg. 2017;43(1):42–8.
Chung JL, Lim EH, Song SW, Kim BY, Lee JH, Mah FS, et al. Comparative intraocular penetration of 4 fluoroquinolones after topical instillation. Cornea. 2013;32(7):1046–51.
Gungor SG, Akova YA, Bozkurt A, Yasar U, Babaoglu MO, Cetinkaya A, et al. Aqueous humour penetration of moxifloxocin and gatifloxacin eye drops in different dosing regimens before phacoemulsification surgery. Br J Ophthalmol. 2011;95(9):1272–5.
Miller JJ, Scott IU, Flynn HW Jr, Smiddy WE, Newton J, Miller D. Acute-onset endophthalmitis after cataract surgery (2000-2004): incidence, clinical settings, and visual acuity outcomes after treatment. Am J Ophthalmol. 2005;139(6):983–7.
Wallin T, Parker J, Jin Y, Kefalopoulos G, Olson RJ. Cohort study of 27 cases of endophthalmitis at a single institution. J Cataract Refract Surg. 2005;31(4):735–41.
Lalitha P, Rajagopalan J, Prakash K, Ramasamy K, Prajna NV, Srinivasan M. Postcataract endophthalmitis in South India incidence and outcome. Ophthalmology. 2005;112(11):1884–9.
Gower EW, et al. Perioperative antibiotics for prevention of acute endophthalmitis after cataract surgery. Cochrane Database Syst Rev. 2017;2:Cd006364.
Barry P, Seal DV, Gettinby G, Lees F, Peterson M, Revie CW, et al. ESCRS study of prophylaxis of postoperative endophthalmitis after cataract surgery: preliminary report of principal results from a European multicenter study. J Cataract Refract Surg. 2006;32(3):407–10.
Herrinton LJ, Shorstein NH, Paschal JF, Liu L, Contreras R, Winthrop KL, et al. Comparative effectiveness of antibiotic prophylaxis in cataract surgery. Ophthalmology. 2016;123(2):287–94.
Kessel L, Flesner P, Andresen J, Erngaard D, Tendal B, Hjortdal J. Antibiotic prevention of postcataract endophthalmitis: a systematic review and meta-analysis. Acta Ophthalmol. 2015;93(4):303–17.
Huang J, Wang X, Chen X, Song Q, Liu W, Lu L. Perioperative antibiotics to prevent acute endophthalmitis after ophthalmic surgery: a systematic review and meta-analysis. PLoS One. 2016;11(11):e0166141.
ASCRS, ASCRS Clinical Survey 2016. Eyeworld Supplements. 2016.
Wong DC, Waxman MD, Herrinton LJ, Shorstein NH. Transient macular edema after intracameral injection of a moderately elevated dose of cefuroxime during phacoemulsification surgery. JAMA Ophthalmol. 2015;133(10):1194–7.
Cakir B, et al. Toxic anterior segment syndrome after uncomplicated cataract surgery possibly associated with intracamaral use of cefuroxime. Clin Ophthalmol. 2015;9:493–7.
Delyfer MN, Rougier MB, Leoni S, Zhang Q, Dalbon F, Colin J, et al. Ocular toxicity after intracameral injection of very high doses of cefuroxime during cataract surgery. J Cataract Refract Surg. 2011;37(2):271–8.
Lockington D, Flowers H, Young D, Yorston D. Assessing the accuracy of intracameral antibiotic preparation for use in cataract surgery. J Cataract Refract Surg. 2010;36(2):286–9.
Matsuura K, Suto C, Akura J, Inoue Y. Comparison between intracameral moxifloxacin administration methods by assessing intraocular concentrations and drug kinetics. Graefes Arch Clin Exp Ophthalmol. 2013;251(8):1955–9.
Montan PG, Wejde G, Setterquist H, Rylander M, Zetterström C. Prophylactic intracameral cefuroxime. Evaluation of safety and kinetics in cataract surgery. J Cataract Refract Surg. 2002;28(6):982–7.
Murphy CC, Nicholson S, Quah SA, Batterbury M, Neal T, Kaye SB. Pharmacokinetics of vancomycin following intracameral bolus injection in patients undergoing phacoemulsification cataract surgery. Br J Ophthalmol. 2007;91(10):1350–3.
Prophylaxis of postoperative endophthalmitis following cataract surgery: results of the ESCRS multicenter study and identification of risk factors. J Cataract Refract Surg. 2007;33(6):978–88.
Montan PG, Wejde G, Koranyi G, Rylander M. Prophylactic intracameral cefuroxime. Efficacy in preventing endophthalmitis after cataract surgery. J Cataract Refract Surg. 2002;28(6):977–81.
Daien V, Papinaud L, Gillies MC, Domerg C, Nagot N, Lacombe S, et al. Effectiveness and safety of an Intracameral injection of cefuroxime for the prevention of endophthalmitis after cataract surgery with or without perioperative capsular rupture. JAMA Ophthalmol. 2016;134(7):810–6.
Ng AL, et al. Intracameral cefuroxime in the prevention of postoperative endophthalmitis: an experience from Hong Kong. Graefes Arch Clin Exp Ophthalmol. 2016;254(10):1987–92.
Rodriguez-Caravaca G, et al. Incidence of endophthalmitis and impact of prophylaxis with cefuroxime on cataract surgery. J Cataract Refract Surg. 2013;39(9):1399–403.
Rock T, et al. Using intracameral cefuroxime reduces postoperative endophthalmitis rate: 5 years experience at the University Eye Hospital Tubingen. Klin Monatsbl Augenheilkd. 2014;231(10):1023–8.
Jabbarvand M, Hashemian H, Khodaparast M, Jouhari M, Tabatabaei A, Rezaei S. Endophthalmitis occurring after cataract surgery: outcomes of more than 480 000 cataract surgeries, epidemiologic features, and risk factors. Ophthalmology. 2016;123(2):295–301.
Sharma S, Sahu SK, Dhillon V, Das S, Rath S. Reevaluating intracameral cefuroxime as a prophylaxis against endophthalmitis after cataract surgery in India. J Cataract Refract Surg. 2015;41(2):393–9.
Matsuura K, Miyoshi T, Suto C, Akura J, Inoue Y. Efficacy and safety of prophylactic intracameral moxifloxacin injection in Japan. J Cataract Refract Surg. 2013;39(11):1702–6.
Au CP, White AJ, Healey PR. Efficacy and cost-effectiveness of intracameral vancomycin in reducing postoperative endophthalmitis incidence in Australia. Clin Exp Ophthalmol. 2016;44(9):803–11.
Haripriya A, Chang DF, Namburar S, Smita A, Ravindran RD. Efficacy of Intracameral moxifloxacin endophthalmitis prophylaxis at Aravind Eye Hospital. Ophthalmology. 2016;123(2):302–8.
Tan CS, Wong HK, Yang FP. Epidemiology of postoperative endophthalmitis in an Asian population: 11-year incidence and effect of intracameral antibiotic agents. J Cataract Refract Surg. 2012;38(3):425–30.
Garat M, Moser CL, Martín-Baranera M, Alonso-Tarrés C, Álvarez-Rubio L. Prophylactic intracameral cefazolin after cataract surgery: endophthalmitis risk reduction and safety results in a 6-year study. J Cataract Refract Surg. 2009;35(4):637–42.
Romero-Aroca P, Méndez-Marin I, Salvat-Serra M, Fernández-Ballart J, Almena-Garcia M, Reyes-Torres J. Results at seven years after the use of intracamerular cefazolin as an endophthalmitis prophylaxis in cataract surgery. BMC Ophthalmol. 2012;12:2.
• Witkin AJ, et al. Vancomycin-associated hemorrhagic occlusive retinal vasculitis: clinical characteristics of 36 eyes. Ophthalmology. 2017;124(5):583–95. This case series identified 36 eyes of 23 patients diagnosed with hemorrhagic occlusive retinal vasculitis (HORV) following routine use of intracameral vancomycin during cataract surgery. These eyes had delayed-onset vision loss with devastating consequences: 61% had final visual acuity of 20/200 or worse. Because of this study, the Americian Society of Cataract and Refractive Surgeons (ASCRS) recommended against the use of intracameral vancomycin during cataract surgery.
Schwartz SG, Relhan N, O’Brien TP, Flynn HW Jr. A new complication associated with the use of prophylactic Intracameral antibiotics: hemorrhagic occlusive retinal vasculitis. Ophthalmology. 2017;124(5):578–9.
•• Haripriya A, Chang DF, Ravindran RD. Endophthalmitis reduction with intracameral moxifloxacin prophylaxis: analysis of 600 000 surgeries. Ophthalmology. 2017;124(6):768–75. This retrospective study of over 600,000 patients demonstrated that intracameral moxifloxacin reduced the postoperative endophthalmitis rate by 3.5-fold. Moxifloxacin is of particular interest because it does not have to be compounded by a pharmacy and, thus, precludes dilution errors.
Libre PE, Mathews S. Endophthalmitis prophylaxis by intracameral antibiotics: in vitro model comparing vancomycin, cefuroxime, and moxifloxacin. J Cataract Refract Surg. 2017;43(6):833–8.
Lipnitzki I, Bronshtein R, Ben Eliahu S, Marcovich AL, Kleinmann G. Hydrophilic acrylic intraocular lens as a drug delivery system: influence of the presoaking time and comparison to intracameral injection. J Ocul Pharmacol Ther. 2013;29(4):414–8.
Kashiwabuchi FK, Khan YA, Rodrigues MW, Wang J, McDonnell PJ, Daoud YJ. Seidel and India ink tests assessment of different clear cornea side-port incision configurations. Graefes Arch Clin Exp Ophthalmol. 2013;251(8):1961–5.
McDonnell PJ, Taban M, Sarayba M, Rao B, Zhang J, Schiffman R, et al. Dynamic morphology of clear corneal cataract incisions. Ophthalmology. 2003;110(12):2342–8.
Herretes S, Stark WJ, Pirouzmanesh A, Reyes JMG, McDonnell PJ, Behrens A. Inflow of ocular surface fluid into the anterior chamber after phacoemulsification through sutureless corneal cataract wounds. Am J Ophthalmol. 2005;140(4):737–40.
Wang M, Liu W, Lu QJ, Zeng HY, Liu SM, Yue YK, et al. Pharmacokinetic comparison of ketorolac after intracameral, intravitreal, and suprachoroidal administration in rabbits. Retina. 2012;32(10):2158–64.
Tyson SL, Bailey R, Roman JS, Zhan T, Hark LA, Haller JA. Clinical outcomes after injection of a compounded pharmaceutical for prophylaxis after cataract surgery: a large-scale review. Curr Opin Ophthalmol. 2017;28(1):73–80.
Conrady CD, Feistmann JA, Roller AB, Boldt HC, Shakoor A. Hemorrhagic vasculitis and retinopathy heralding as an early sign of bacterial endophthalmitis after intravitreal injection. Retin Cases Brief Rep. 2017:1.
Conrady CD, Hanson KE, Mehra S, Carey A, Larochelle M, Shakoor A. The first case of Trypanosoma cruzi-associated retinitis in an immunocompromised host diagnosed by pan-organism PCR. Clin Infect Dis. 2018;(In press).
Poulsen EJ, Allingham RR. Characteristics and risk factors of infections after glaucoma filtering surgery. J Glaucoma. 2000;9(6):438–43.
Sunaric-Megevand G, Pournaras CJ. Current approach to postoperative endophthalmitis. Br J Ophthalmol. 1997;81(11):1006–15.
Hanscom TA. Postoperative endophthalmitis. Clin Infect Dis. 2004;38(4):542–6.
Nishida T, et al. An eleven-year retrospective study of endogenous bacterial endophthalmitis. J Ophthalmol. 2015;2015:261310.
Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Endophthalmitis Vitrectomy Study Group. Arch Ophthalmol. 1995;113(12):1479–96.
Zhang YQ, Wang WJ. Treatment outcomes after pars plana vitrectomy for endogenous endophthalmitis. Retina. 2005;25(6):746–50.
Benz MS, Scott IU, Flynn HW Jr, Unonius N, Miller D. Endophthalmitis isolates and antibiotic sensitivities: a 6-year review of culture-proven cases. Am J Ophthalmol. 2004;137(1):38–42.
Jackson TL, Eykyn SJ, Graham EM, Stanford MR. Endogenous bacterial endophthalmitis: a 17-year prospective series and review of 267 reported cases. Surv Ophthalmol. 2003;48(4):403–23.
Doft BH, Barza M. Ceftazidime or amikacin: choice of intravitreal antimicrobials in the treatment of postoperative endophthalmitis. Arch Ophthalmol. 1994;112(1):17–8.
Barza M, Pavan PR, Doft BH, Wisniewski SR, Wilson LA, Han DP, et al. Evaluation of microbiological diagnostic techniques in postoperative endophthalmitis in the Endophthalmitis Vitrectomy Study. Arch Ophthalmol. 1997;115(9):1142–50.
Haider SA, Hassett P, Bron AJ. Intraocular vancomycin levels after intravitreal injection in post cataract extraction endophthalmitis. Retina. 2001;21(3):210–3.
Hashemian H, Mirshahi R, Khodaparast M, Jabbarvand M. Post-cataract surgery endophthalmitis: brief literature review. J Curr Ophthalmol. 2016;28(3):101–5.
Escariao P, Commodaro AG, Arantes T, CMMB C, MFA D, Brandt CT. Analysis of cytokines in presumed acute infectious endophthalmitis following cataract extraction. J Clin Exp Ophthalmol. 2014;5:335.
• Rayess N, Rahimy E, Storey P, Shah CP, Wolfe JD, Chen E, et al. Post-injection endophthalmitis rates and characteristics following intravitreal bevacizumab, ranibizumab and aflibercept. Am J Ophthalmol. 2016. This large retrospective study helped to define rates and visual outcomes of post-injection endophthalmitis that were similar amongst all anti-VEGF agents with rates between 0.035 and 0.039%.;165:88–93.
Jackson TL, Paraskevopoulos T, Georgalas I. Systematic review of 342 cases of endogenous bacterial endophthalmitis. Surv Ophthalmol. 2014;59(6):627–35.
Ravindran RD, Venkatesh R, Chang DF, Sengupta S, Gyatsho J, Talwar B. Incidence of post-cataract endophthalmitis at Aravind Eye Hospital: outcomes of more than 42,000 consecutive cases using standardized sterilization and prophylaxis protocols. J Cataract Refract Surg. 2009;35(4):629–36.
Moshirfar M, Feiz V, Vitale AT, Wegelin JA, Basavanthappa S, Wolsey DH. Endophthalmitis after uncomplicated cataract surgery with the use of fourth-generation fluoroquinolones: a retrospective observational case series. Ophthalmology. 2007;114(4):686–91.
Kuhn F, Gini G. Vitrectomy for endophthalmitis. Ophthalmology. 2006;113(4):714.
Doft BH, Wisniewski SR, Kelsey SF, Fitzgerald SG, Endophthalmitis Vitrectomy Study Group. Diabetes and postoperative endophthalmitis in the endophthalmitis vitrectomy study. Arch Ophthalmol. 2001;119(5):650–6.
•• Shalaby A, Di Simplicio Cherubini S, Lockwood A, Newsom R. Postoperative endophthalmitis: incidence, causes and comparison between medical and surgical treatment in a United Kingdom region in the last 10 years. Acta Ophthalmol. 2015;93(S255) This paper was a retrospective case review of 60 patients with endophthalmitis from various causes in which the patients with count fingers vision or worse vision that received vitrectomy had significantly better visual outcomes than those that only received intravitreal antibiotics. This raises questions as to whether the presenting visual acuity guidelines should be altered to guide clinicians on when to perform a vitrectomy.
DeBry PW, et al. Incidence of late-onset bleb-related complications following trabeculectomy with mitomycin. Arch Ophthalmol. 2002;120(3):297–300.
Kangas TA, et al. Delayed-onset endophthalmitis associated with conjunctival filtering blebs. Ophthalmology. 1997;104(5):746–52.
Waheed S, Ritterband DC, Greenfield DS, Liebmann JM, Seedor JA, Ritch R. New patterns of infecting organisms in late bleb-related endophthalmitis: a ten year review. Eye (Lond). 1998;12(Pt 6):910–5.
Ciulla TA, Beck AD, Topping TM, Baker AS. Blebitis, early endophthalmitis, and late endophthalmitis after glaucoma-filtering surgery. Ophthalmology. 1997;104(6):986–95.
Ohtomo K, et al. Outcomes of late-onset bleb-related endophthalmitis treated with pars plana vitrectomy. J Ophthalmol. 2015;2015:923857.
Ba’arah BT, Smiddy WE. Bleb-related endophthalmitis: clinical presentation, isolates, treatment and visual outcome of culture-proven cases. Middle East Afr J Ophthalmol. 2009;16(1):20–4.
Song A, Scott IU, Flynn MPHHW Jr, Budenz DL. Delayed-onset bleb-associated endophthalmitis: clinical features and visual acuity outcomes. Ophthalmology. 2002;109(5):985–91.
Busbee BG, et al. Bleb-associated endophthalmitis: clinical characteristics and visual outcomes. Ophthalmology. 2004;111(8):1495–503. discussion 1503
Meisler DM, Zakov ZN, Bruner WE, Hall GS, McMahon JT, Zachary AA, et al. Endophthalmitis associated with sequestered intraocular Propionibacterium acnes. Am J Ophthalmol. 1987;104(4):428–9.
Al-Mezaine HS, Al-Assiri A, Al-Rajhi AA. Incidence, clinical features, causative organisms, and visual outcomes of delayed-onset pseudophakic endophthalmitis. Eur J Ophthalmol. 2009;19(5):804–11.
Aldave AJ, Stein JD, Deramo VA, Shah GK, Fischer DH, Maguire JI. Treatment strategies for postoperative Propionibacterium acnes endophthalmitis. Ophthalmology. 1999;106(12):2395–401.
Clark WL, Kaiser PK, Flynn HW Jr, Belfort A, Miller D, Meisler DM. Treatment strategies and visual acuity outcomes in chronic postoperative Propionibacterium acnes endophthalmitis. Ophthalmology. 1999;106(9):1665–70.
Busin M. Antibiotic irrigation of the capsular bag to resolve low-grade endophthalmitis. J Cataract Refract Surg. 1996;22(3):385–9.
Arsan AK, Sizmaz S, Ozkan SB, Duman S. Corynebacterium minutissimum endophthalmitis: management with antibiotic irrigation of the capsular bag. Int Ophthalmol. 1995;19(5):313–6.
Lingappan A, et al. Endogenous fungal endophthalmitis: causative organisms, management strategies, and visual acuity outcomes. Am J Ophthalmol. 2012;153(1):162–6 e1.
Romero CF, Rai MK, Lowder CY, Adal KA. Endogenous endophthalmitis: case report and brief review. Am Fam Physician. 1999;60(2):510–4.
Essman TF, Flynn HW Jr, Smiddy WE, Brod RD, Murray TG, Davis JL, et al. Treatment outcomes in a 10-year study of endogenous fungal endophthalmitis. Ophthalmic Surg Lasers. 1997;28(3):185–94.
Paulus YM, Cheng S, Karth PA, Leng T. Prospective trial of endogenous fungal endophthalmitis and chorioretinitis rates, clinical course, and outcomes in patients with fungemia. Retina. 2016;36(7):1357–63.
• Pappas PG, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1–50. This practice guideline helped define appropriate treatment for intraocular candidiasis.
Bronner S, Jehl F, Peter JD, Ploy MC, Renault C, Arvis P, et al. Moxifloxacin efficacy and vitreous penetration in a rabbit model of Staphylococcus aureus endophthalmitis and effect on gene expression of leucotoxins and virulence regulator factors. Antimicrob Agents Chemother. 2003;47(5):1621–9.
Hariprasad SM, Mieler WF, Holz ER. Vitreous and aqueous penetration of orally administered gatifloxacin in humans. Arch Ophthalmol. 2003;121(3):345–50.
Narang S, Gupta A, Gupta V, Dogra MR, Ram J, Pandav SS, et al. Fungal endophthalmitis following cataract surgery: clinical presentation, microbiological spectrum, and outcome. Am J Ophthalmol. 2001;132(5):609–17.
Brar GS, Ram J, Kaushik S, Chakraborti A, Dogra MR, Gupta A. Aspergillus niger endophthalmitis after cataract surgery. J Cataract Refract Surg. 2002;28(10):1882–3.
Lin RC, Sanduja N, Hariprasad SM. Successful treatment of postoperative fungal endophthalmitis using intravitreal and intracameral voriconazole. J Ocul Pharmacol Ther. 2008;24(2):245–8.
Riddell Jt, Comer GM, Kauffman CA. Treatment of endogenous fungal endophthalmitis: focus on new antifungal agents. Clin Infect Dis. 2011;52(5):648–53.
Breit SM, Hariprasad SM, Mieler WF, Shah GK, Mills MD, Grand MG. Management of endogenous fungal endophthalmitis with voriconazole and caspofungin. Am J Ophthalmol. 2005;139(1):135–40.
Aydin S, Ertugrul B, Gultekin B, Uyar G, Kir E. Treatment of two postoperative endophthalmitis cases due to Aspergillus flavus and Scopulariopsis spp. with local and systemic antifungal therapy. BMC Infect Dis. 2007;7:87.
Doft BM, Kelsey SF, Wisniewski SR. Retinal detachment in the endophthalmitis vitrectomy study. Arch Ophthalmol. 2000;118(12):1661–5.
Hariprasad SM, Shah GK, Mieler WF, Feiner L, Blinder KJ, Holekamp NM, et al. Vitreous and aqueous penetration of orally administered moxifloxacin in humans. Arch Ophthalmol. 2006;124(2):178–82.
Yagci R, et al. Penetration of second-, third-, and fourth-generation topical fluoroquinolone into aqueous and vitreous humour in a rabbit endophthalmitis model. Eye (Lond). 2007;21(7):990–4.
De Kaspar HM, et al. Effects of intravitreal corticosteroid in the treatment of Staphylococcus aureus-induced experimental endophthalmitis. Retina. 2008;28(2):326–32.
Smith MA, Sorenson JA, D’Aversa G, Mandelbaum S, Udell I, Harrison W. Treatment of experimental methicillin-resistant Staphylococcus epidermidis endophthalmitis with intravitreal vancomycin and intravitreal dexamethasone. J Infect Dis. 1997;175(2):462–6.
Meredith TA, et al. Intraocular dexamethasone produces a harmful effect on treatment of experimental Staphylococcus aureus endophthalmitis. Trans Am Ophthalmol Soc. 1996;94:241–52. discussion 252–7
Graham RO, Peyman GA. Intravitreal injection of dexamethasone. Treatment of experimentally induced endophthalmitis. Arch Ophthalmol. 1974;92(2):149–54.
Kim IT, Chung KH, Koo BS. Efficacy of ciprofloxacin and dexamethasone in experimental pseudomonas endophthalmitis. Korean J Ophthalmol. 1996;10(1):8–17.
Das T, Jalali S, Gothwal VK, Sharma S, Naduvilath TJ. Intravitreal dexamethasone in exogenous bacterial endophthalmitis: results of a prospective randomised study. Br J Ophthalmol. 1999;83(9):1050–5.
Gan IM, Ugahary LC, van Dissel JT, Feron E, Peperkamp E, Veckeneer M, et al. Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: a prospective randomized trial. Graefes Arch Clin Exp Ophthalmol. 2005;243(12):1200–5.
Albrecht E, Richards JC, Pollock T, Cook C, Myers L. Adjunctive use of intravitreal dexamethasone in presumed bacterial endophthalmitis: a randomised trial. Br J Ophthalmol. 2011;95(10):1385–8.
Jacobs DJ, et al. Intravitreal dexamethasone in the management of delayed-onset bleb-associated endophthalmitis. Int J Inflamm. 2012;2012:503912.
Altan T, Kapran Z, Eser I, Acar N, Ünver YB, Yurttaser S. Comparative outcomes of pars plana vitrectomy in acute postoperative endophthalmitis with 25-gauge and 20-gauge techniques. Jpn J Ophthalmol. 2009;53(5):506–11.
Funding
This work was supported in part by an Unrestricted Grant from Research to Prevent Blindness, Inc., New York, NY, to the Department of Ophthalmology & Visual Sciences, University of Utah. This source of financial support had no role in the study design; the collection, analysis, or interpretation of data; in the writing of the report; or the decision to submit the article for publication.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
This article is part of the Topical Collection on Ocular Microbiology and Immunology
Rights and permissions
About this article
Cite this article
Brundrett, A., Conrady, C.D., Shakoor, A. et al. Current Strategies for Prevention and Treatment of Postoperative Endophthalmitis. Curr Ophthalmol Rep 6, 105–114 (2018). https://doi.org/10.1007/s40135-018-0171-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40135-018-0171-6